Besides, many CAR-T phase I and phase II clinical trials for pediatric and adult’s B-cell lymphoma are under recruiting status and the majority of them are anti-CD19 CAR-T trials (Table 3) [13]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.